Journal article · 2026

Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer

Maurice Pérol, Tatsuya Yoshida, Myung-Ju Ahn, Carl Michael Gay, Martin Schüler, Haifeng Liu, Ahmet Sezer, Ahmet Erkan Bilici, Ippokratis Korantzis, Sun Min Lim, Kohei Otsubo, Óscar Juan and 11 more

New England Journal of Medicine · Published 24 October 2026 · DOI 10.1056/nejmoa2609482

View at the publisherCite this paper

In brief

“Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer” is a 2026 journal article by Maurice Pérol and 22 co-authors, published in New England Journal of Medicine. OpenAlex counts 3 citations as of 16 November 2026, which puts it in the top 4% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
3
Most cited in
2026 (3)
Field-weighted impact
7.20
References
13
Authors
23

Abstract

BACKGROUND: Patients with extensive-stage small-cell lung cancer have poor outcomes, with a median overall survival of approximately 12 to 13 months. Tarlatamab (a bispecific T-cell engager targeting delta-like ligand 3 [DLL3] and CD3) was previously shown to improve survival as second-line therapy. Whether adding tarlatamab to durvalumab (an anti-programmed death ligand 1 agent) after initial… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Pérol, M., Yoshida, T., Ahn, M.-J., Gay, C. M., Schüler, M., Liu, H., Sezer, A., Bilici, A. E., Korantzis, I., Lim, S. M., Otsubo, K., Juan, Ó., Chen, Y., Schvartsman, G., Wang, H., Dingemans, A. C., Clarke, J. M., Desai, A. P., Marigil, M., . . . Sands, J. M. (2026). Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609482

MLA 9

Pérol, Maurice, et al. “Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2609482.

Chicago

Pérol, Maurice, Tatsuya Yoshida, Myung-Ju Ahn, Carl Michael Gay, Martin Schüler, Haifeng Liu, Ahmet Sezer, et al. 2026. “Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609482.

Harvard

Pérol, M. et al. (2026) ‘Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer’, New England Journal of Medicine. doi:10.1056/nejmoa2609482.

IEEE

M. Pérol et al., “Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2609482.

BibTeX

@article{perol2026tarlatamab,
  title     = {{Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer}},
  author    = {Pérol, Maurice and Yoshida, Tatsuya and Ahn, Myung-Ju and Gay, Carl Michael and Schüler, Martin and Liu, Haifeng and Sezer, Ahmet and Bilici, Ahmet Erkan and Korantzis, Ippokratis and Lim, Sun Min and Otsubo, Kohei and Juan, Óscar and Chen, Yuanbin and Schvartsman, Gustavo and Wang, Haiyong and Dingemans, Anne‐Marie C. and Clarke, Jeffrey Melson and Desai, Aakash P. and Marigil, Miguel and Chen, Yuqi and Abidi, Bazle and Wang, Jessie and Sands, Jacob M.},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  doi       = {10.1056/nejmoa2609482},
  url       = {https://doi.org/10.1056/nejmoa2609482}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Lung Cancer Research Studies

  • tarlatamab
  • durvalumab
  • extensive-stage small cell lung cancer
  • maintenance therapy
  • bispecific T-cell engagers
  • DLL3
  • PD-L1 blockade
  • chemoimmunotherapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Pérol, M., Yoshida, T., Ahn, M.-J., Gay, C. M., Schüler, M., Liu, H., Sezer, A., Bilici, A. E., Korantzis, I., Lim, S. M., Otsubo, K., Juan, Ó., Chen, Y., Schvartsman, G., Wang, H., Dingemans, A. C., Clarke, J. M., Desai, A. P., Marigil, M., . . . Sands, J. M. (2026). Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609482

How many times has this paper been cited?

3 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Maurice Pérol, Tatsuya Yoshida, Myung-Ju Ahn, Carl Michael Gay, Martin Schüler, Haifeng Liu, Ahmet Sezer, Ahmet Erkan Bilici, Ippokratis Korantzis, Sun Min Lim, Kohei Otsubo, Óscar Juan and 11 more.

What is the DOI of this paper?

10.1056/nejmoa2609482, permanently at https://doi.org/10.1056/nejmoa2609482. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.